🔎 Trials Near Me

Início › Leucemia Mieloide Aguda › Carolina do Sul › Greenville

Ensaios clínicos de Leucemia Mieloide Aguda em Greenville, SC

10 estudos para Leucemia Mieloide Aguda estão buscando participantes em locais em Greenville e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.

Texto oficial do estudo (Inglês)

Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

RecrutandoFase 2
  • Prisma Health Cancer Institute - Butternut, Greenville
  • Prisma Health Cancer Institute - Faris, Greenville
  • Prisma Health Cancer Institute - Eastside, Greenville
Idades 18 e acima · Todos os sexos · Atualizado em 5 de out. de 2026 · NCT05564390

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
  • Prisma Health Cancer Institute - Faris, Greenville
  • Prisma Health Greenville Memorial Hospital, Greenville
Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

RecrutandoFase 2
  • Prisma Health Cancer Institute - Butternut, Greenville
  • Prisma Health Cancer Institute - Faris, Greenville
  • Prisma Health Cancer Institute - Eastside, Greenville
Idades de 18 a 59 · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT05554393

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

RecrutandoFase 2
  • Prisma Health Cancer Institute - Butternut, Greenville
  • Prisma Health Cancer Institute - Faris, Greenville
  • Prisma Health Cancer Institute - Eastside, Greenville
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

RecrutandoFase 2
  • Prisma Health Cancer Institute - Butternut, Greenville
  • Prisma Health Cancer Institute - Faris, Greenville
  • Prisma Health Cancer Institute - Eastside, Greenville
Idades de 18 a 59 · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT05554406

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

RecrutandoFase 2
  • Prisma Health Cancer Institute - Butternut, Greenville
  • Prisma Health Cancer Institute - Faris, Greenville
  • Prisma Health Cancer Institute - Eastside, Greenville
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06317649

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

RecrutandoFase 3
  • BI-LO Charities Children's Cancer Center, Greenville
6 Months – 21 Years · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT04293562

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

RecrutandoFase 1/2
  • Bon Secours St. Francis Cancer Center, Greenville
Idades 12 e acima · Todos os sexos · Atualizado em 3 de set. de 2026 · NCT04588922

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

RecrutandoFase 1
  • Prisma Health, Greenville
Idades 18 e acima · Todos os sexos · Atualizado em 20 de ago. de 2026 · NCT06001788

Ensaios de Leucemia Mieloide Aguda em outras cidades

Outros estudos em Greenville

Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.